10 Best ASX Stocks to Buy According to Hedge Funds

8. Immutep Limited (NASDAQ:IMMP)

Number of Hedge Fund Holdings: 2

Immutep Limited (NASDAQ:IMMP) is a biotechnology company headquartered in Australia, specializing in immunotherapy treatments for cancer and autoimmune diseases. Their lead product, eftilagimod alpha (efti), is a soluble LAG-3 protein that aims to enhance the immune system’s ability to fight cancer. Immutep Limited’s (NASDAQ:IMMP) pipeline includes several immunotherapy candidates, developed in collaboration with pharmaceutical partners and targets various cancer types and autoimmune conditions.

Immutep Limited (NASDAQ:IMMP) is concentrating on non-small cell lung cancer, a widespread and aggressive form of cancer. The company has made significant strides with its phase 1 INSIGHT-003 study, which assessed the combination of efti, KEYTRUDA, and chemotherapy in first-line metastatic non-squamous patients. The results have been highly encouraging and have shown benefits across all PD-L1 expression levels, which laid the groundwork for the phase 3 TACTI-004 study, designed to further validate these findings and potentially establish efti as a new standard of care for patients.

Immutep Limited (NASDAQ:IMMP) is also investigating the potential of efti in treating other cancers and autoimmune conditions. The company has already achieved positive results in its phase 2b TACTI-003 study, where efti, in combination with KEYTRUDA, was used to treat first-line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Additionally, Immutep Limited (NASDAQ:IMMP) is exploring the application of efti in the neoadjuvant setting for resectable soft tissue sarcoma (STS), where it has demonstrated the ability to achieve three-fold higher levels of hyalinization/fibrosis compared to historical radiotherapy controls.